98%
921
2 minutes
20
While Huntington's disease (HD), a Mendelian disorder caused by an expanded CAG repeat in , is considered rare, the true prevalence could be significantly higher due to substantial underascertainment. Given inherent biases in empirically assessing disease prevalence, we performed mathematical modelling and validation analyses to estimate the frequency of expanded CAG repeats in the general population to better understand the disease prevalence. We developed an exponential decay model after confirming that the logarithmic decrease in frequency of CAG repeats extends into the pathogenic range (CAG > 35). The model was further refined by incorporating HD onset and mortality probabilities to estimate the clinical ascertainment rate. Our age-adjusted exponential decay model estimated one expanded repeat in 325 people and further showed that the frequency of expanded repeats decreases with age due to the early mortality associated with HD, which was validated by All of Us and UK Biobank data. Importantly, our data suggest that approximately half of symptomatic HD individuals aged 30-70 are not clinically ascertained/diagnosed. Our data, showing higher frequencies of expanded repeats in the general population and significant underascertainment rates, imply that HD prevalence could be twice as high as current estimates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123046 | PMC |
http://dx.doi.org/10.1093/braincomms/fcaf194 | DOI Listing |
Eur J Med Chem
August 2025
Amity Institute of Pharmacy, Amity University Haryana, 122413, India. Electronic address:
Neurodegenerative diseases (NDs), including Alzheimer's, Huntington's, and Parkinson's disease, are associated with significant declines in cognitive function and mobility. The accumulation of misfolded proteins such as β-amyloid, tau, α-synuclein, and polyglutamates is a key factor in the progression of these conditions. Unfortunately, traditional small-molecule drugs face major obstacles in effectively targeting these proteins.
View Article and Find Full Text PDFParkinsonism Relat Disord
September 2025
Federal University of São Paulo, Department of Neurology and Neurosurgery, São Paulo, SP, Brazil.
Background: Huntington disease-like 2 (HDL2) is an autosomal dominant disorder caused by an abnormal CAG/CTG repeat in exon 2A of junctophilin-3. This is the most common Huntington's Disease phenocopy and is characterized by psychiatric, cognitive, and movement disorders. This study aimed to describe the clinical phenotype of HDL2 patients in Brazil and compare the findings with those in the literature.
View Article and Find Full Text PDFNeurogenetics
September 2025
Nur International University, 54600, Lahore, Punjab, Pakistan.
Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric disturbances. It is caused by CAG repeat expansions in the HTT gene, resulting in the formation of mutant huntingtin protein that aggregates and disrupts neuronal function. This review outlines the pathogenesis of HD, including genetic, molecular, and environmental factors.
View Article and Find Full Text PDFFASEB J
September 2025
Department of Aerospace and Mechanical Engineering, University of Southern California, Los Angeles, California, USA.
Myocardial infarction (MI) is a leading cause of death worldwide and the most common precursor to heart failure, even after initial treatment. Precise evaluation of myocardial injury is crucial for assessing interventions and improving outcomes. Extensive evidence from both preclinical models and clinical studies demonstrates that the extent and severity of myocardial injury (i.
View Article and Find Full Text PDFNat Med
September 2025
Prilenia Therapeutics B.V., Naarden, the Netherlands.
Huntington's disease (HD) is a rare, neurodegenerative disorder for which only symptomatic treatments are available. The PROOF-HD study was a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy and safety of pridopidine, a selective Sigma-1 receptor agonist, in HD. The primary and key secondary endpoints, change in total functional capacity (TFC) and composite Unified Huntington's Disease Rating Scale (cUHDRS) score at week 65, were not met in the overall population.
View Article and Find Full Text PDF